Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP)
51.35
-8.23 (-13.81%)
NASDAQ · Last Trade: Aug 17th, 11:35 PM EDT
Detailed Quote
| Previous Close | 59.58 |
|---|---|
| Open | 51.92 |
| Bid | 59.05 |
| Ask | 59.82 |
| Day's Range | 45.22 - 53.50 |
| 52 Week Range | 6.760 - 130.00 |
| Volume | 4,836,368 |
| Market Cap | 450.13M |
| PE Ratio (TTM) | -0.2871 |
| EPS (TTM) | -178.9 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,828,470 |
Chart
About Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP)
Tonix Pharmaceuticals Holdings is a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system disorders and other serious medical conditions. The company is dedicated to advancing its pipeline of product candidates, which include treatments for conditions such as migraines, post-traumatic stress disorder, and various infectious diseases. By leveraging its expertise in drug development and utilizing strategic collaborations, Tonix aims to bring novel treatment options to market that address unmet medical needs and improve patient outcomes. Read More
News & Press Releases
Via Benzinga · August 15, 2025
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via Chartmill · August 15, 2025
Via Benzinga · August 15, 2025
Tonix Pharma Scores Best Day Since March On Hopes For First New Fibromyalgia Drug Approval in 16 Years; Retail’s Optimisticstocktwits.com
Via Stocktwits · August 12, 2025
Shares of Tonix Pharmaceuticals have rallied 30% over the past five sessions. Investors are anticipating a key catalyst for the company.
Via Benzinga · August 14, 2025
Shares of Tonix Pharmaceuticals are building on recent gains. The stock is trading higher as investor focus intensifies on a key, upcoming catalyst.
Via Benzinga · August 13, 2025
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via Chartmill · August 12, 2025
Via Benzinga · August 12, 2025
Via Benzinga · August 12, 2025
Shares of Tonix Pharmaceuticals are trading sharply higher Tuesday morning. The stock is gaining following the release of the company's Q2 financial results and operational update.
Via Benzinga · August 12, 2025
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
NetworkNewsWire Editorial Coverage : As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The aging population’s increasing life expectancy also leads to more complex healthcare needs, especially for conditions that are both chronic and difficult to diagnose. Many of these rare conditions lack FDA-approved treatments, and their symptoms in seniors are frequently mistaken for normal signs of aging, causing diagnostic delays that can last for years. There are more than 30 million Americans who have a rare disease, so there is a growing need for accurate diagnoses and effective treatments. The Trump administration’s “Make America Healthy Again” initiatives have highlighted this problem and focused on improving access to treatments and speeding up medical innovation. Soligenix Inc. (NASDAQ: SNGX) ( Profile ) is working to advance this mission with its HyBryte(“TM”) platform, a new therapy for cutaneous T-cell lymphoma (“CTCL”), a rare form of skin cancer that largely impacts older adults. The company has successfully established U.S.-based manufacturing for HyBryte’s active ingredient, demonstrating the kind of domestic innovation that can significantly help this underserved patient group. Soligenix is one of several notable companies dedicated to making an impact in the pharmaceutical field, alongside Amgen Inc. (NASDAQ: AMGN), Amicus Therapeutics Inc. (NASDAQ: FOLD), Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) and…
Via Investor Brand Network · August 6, 2025
EQNX::TICKER_START (NASDAQ:SNGX),(NASDAQ:FOLD),(NASDAQ:TNXP),(NASDAQ:CTOR),(NASDAQ:AMGN) EQNX::TICKER_END
Via FinancialNewsMedia · August 6, 2025
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present TNX-801 Mpox Vaccine Data at Vaccine Congress 2025
Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated biopharmaceutical company, announced that Dr. Sina Bavari, Executive Vice President of Infectious Disease Research and Development, will present new preclinical data on TNX-801 at the Vaccine Congress 2025 in Vienna on July 10. TNX-801, a recombinant horsepox virus live vaccine candidate, has shown protective efficacy against mpox and other orthopoxviruses in animal models after a single dose. The platform is designed to induce durable immune responses and could be expanded to target other emerging viral threats. Dr. Bavari will highlight safety, immunogenicity, and efficacy findings, along with plans to initiate clinical trials.
Via Investor Brand Network · July 7, 2025
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Publishes Preclinical Data Supporting TNX-1700 as Immunotherapy Enhancer in Gastric Cancer
Tonix Pharmaceuticals (NASDAQ: TNXP), a biopharmaceutical company advancing immunotherapy resistance solutions, announced the publication of new preclinical findings in Cancer Cell showing its fusion protein candidate mTNX-1700 increased survival and reduced metastases in mouse models of gastric cancer. Developed in collaboration with Columbia University Medical School, mTNX-1700—comprising murine trefoil factor-2 (mTFF2) and murine serum albumin—enhanced anti-PD-1 immunotherapy by depleting immunosuppressive neutrophils and curbing cancer-driven granulopoiesis. The human version, TNX-1700, is in development for gastric and colorectal cancers. CEO Dr. Seth Lederman said the findings support further development of TNX-1700 to overcome checkpoint resistance in solid tumors.
Via Investor Brand Network · July 2, 2025
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Added to Russell 3000 and Russell 2000 Indexes
Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated biotech company, announced its inclusion in the Russell 3000® and Russell 2000® Indexes following the 2025 Russell indexes reconstitution effective June 30. The addition reflects Tonix’s market cap growth and comes as the company prepares for potential FDA approval and launch of TNX-102 SL for fibromyalgia. CEO Seth Lederman noted the milestone will boost visibility as Tonix progresses toward commercialization. Russell indexes are widely used benchmarks, with $10.6 trillion in assets tied to their performance.
Via Investor Brand Network · June 30, 2025
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Phase 3 Data on Fibromyalgia Drug at EULAR 2025
Tonix Pharmaceuticals (NASDAQ: TNXP) presented new data at the 2025 Annual European Congress of Rheumatology (EULAR) in Barcelona supporting TNX-102 SL, its sublingual cyclobenzaprine formulation for fibromyalgia. The poster highlighted results from the RESILIENT Phase 3 trial showing statistically significant, sustained pain reduction over 14 weeks, along with improved sleep and favorable tolerability. Designed to bypass first-pass liver metabolism, TNX-102 SL achieved higher nighttime cyclobenzaprine levels and lower norcyclobenzaprine accumulation compared to oral formulations, potentially enhancing long-term efficacy. With a Prescription Drug User Fee Act (PDUFA) goal date of Aug. 15, 2025, TNX-102 SL could become the first new fibromyalgia therapy in 15 years.
Via Investor Brand Network · June 16, 2025
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Appoints Jim Hunter to Board of Directors
Tonix Pharmaceuticals (NASDAQ: TNXP) a fully-integrated biotechnology company with marketed products and late-stage development candidates, announced the appointment of James “Jim” Hunter to its Board of Directors, effective June 12. Hunter previously served as Executive Vice President, Commercial, where he built the Company’s commercial subsidiary, Tonix Medicines, and led its entry into the migraine market. CEO Dr. Seth Lederman cited Hunter’s operational insight and commercial expertise as key assets as the company prepares for a potential launch of TNX-102 SL for fibromyalgia later this year.
Via Investor Brand Network · June 13, 2025
Tonix Pharmaceuticals has filed a registration statement to sell up to $500 million in securities. The company's lead drug candidate is for the management of fibromyalgia pain.
Via Benzinga · June 12, 2025
Via Benzinga · June 12, 2025
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.
Via Chartmill · June 12, 2025
Via Benzinga · June 12, 2025
The proceeds from the purchase agreement are expected to be used for working capital and general corporate purposes.
Via Stocktwits · June 12, 2025
Via Benzinga · June 12, 2025
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at 2025 BIO International Convention
Tonix Pharmaceuticals (NASDAQ: TNXP) announced that CEO Seth Lederman, M.D., will present at the 2025 BIO International Convention in Boston. The presentation is scheduled for Mon., June 16 at 5:00 p.m. in Room 153B at the Boston Convention & Exhibition Center.
Via Investor Brand Network · June 10, 2025
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at EULAR 2025 in Barcelona
Tonix Pharmaceuticals (NASDAQ: TNXP) a fully integrated biotechnology company with commercial and clinical-stage assets, will deliver a poster presentation at the Annual European Congress of Rheumatology (EULAR) 2025, taking place June 11–14 in Barcelona. The company has not yet disclosed full presentation details but noted the research will contribute to advancing its pipeline in rheumatologic conditions.
Via Investor Brand Network · June 5, 2025